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PDK1 regulates growth through Akt and S6K in Drosophila
Abstract
The insulin/insulin-like growth factor-1 signaling pathway promotes growth in invertebrates and
vertebrates by increasing the levels of phosphatidylinositol 3,4,5-triphosphate through the activation of
p110 phosphatidylinositol 3-kinase. Two key effectors of this pathway are the
phosphoinositide-dependent protein kinase 1 (PDK1) and Akt/PKB. Although genetic analysis in
Caenorhabditis elegans has implicated Akt as the only relevant PDK1 substrate, cell culture studies have
suggested that PDK1 has additional targets. Here we show that, in Drosophila, dPDK1 controls cellular
and organism growth by activating dAkt and S6 kinase, dS6K. Furthermore, dPDK1 genetically
interacts with dRSK but not with dPKN, encoding two substrates of PDK1 in vitro. Thus, the results
suggest that dPDK1 is required for dRSK but not dPKN activation and that it regulates insulin-mediated
growth through two main effector branches, dAkt and dS6K.
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The insulininsulin-like growth factor-1 signaling pathway pro-
motes growth in invertebrates and vertebrates by increasing the
levels of phosphatidylinositol 3,4,5-triphosphate through the ac-
tivation of p110 phosphatidylinositol 3-kinase. Two key effectors
of this pathway are the phosphoinositide-dependent protein ki-
nase 1 (PDK1) and AktPKB. Although genetic analysis in Caeno-
rhabditis elegans has implicated Akt as the only relevant PDK1
substrate, cell culture studies have suggested that PDK1 has
additional targets. Here we show that, in Drosophila, dPDK1
controls cellular and organism growth by activating dAkt and S6
kinase, dS6K. Furthermore, dPDK1 genetically interacts with dRSK
but not with dPKN, encoding two substrates of PDK1 in vitro. Thus,
the results suggest that dPDK1 is required for dRSK but not dPKN
activation and that it regulates insulin-mediated growth through
two main effector branches, dAkt and dS6K.
Genetic studies in Caenorhabditis elegans and Drosophila, andbiochemical analyses in vertebrate cell culture systems have
led to the identification of key components of the insulin signal
transduction pathway, including members of the phosphatidyl-
inositol 3-kinase [PI(3)K] signaling pathway; the protein kinases
PDK1, Akt, GSK3, and S6K and the 3-phosphatidylinositide
phosphatase PTEN, which antagonizes the effects of PI(3)K by
converting phosphatidylinositol 3,4,5-triphosphate (PIP3) to
phosphatidylinositol 4,5-biphosphate. In addition, studies in vitro
and in vertebrate cell culture systems have implicated phospho-
inositide-dependent protein kinase 1 (PDK1) as the critical
regulator of T-loop phosphorylation in many members of the
AGC family of kinases, which include Akt (1–6), S6K (7, 8), RSK
(9, 10), PKN (11), and all isoforms of protein kinase C (12–15).
PDK1 possesses two functional domains, a serinethreonine
kinase domain located amino-terminally and a Pleckstrin-
homology domain with a high affinity to PIP3. Owing to this high
affinity to PIP3, PDK1 is located at the membrane even in resting
cells and controls activity of its target kinases at the plasma
membrane (4, 16). Consistent with PDK1 being a direct effector
of Akt, S6K, and RSK, activation of all three kinases is blocked
in PDK1/-deficient embryonic stem cells (17). These findings
imply that in vivo PDK1 has multiple targets and acts as a
downstream branch point for PI(3)K signaling. However, despite
these observations, genetic analyses in C. elegans and a recent
study in Drosophila have implicated Akt as the only relevant
target for PDK1 function (18, 19). In contrast, the detailed
genetic analysis of dPDK1 function in Drosophila presented here
indicates that PDK1 functions as a central regulator of cell
growth by regulating two effector pathways controlled by the
AGC kinases Akt and S6K, respectively.
Methods
Ethyl Methanesulfonate (EMS) Mutagenesis and Analysis of Mutants.
To generate mutations in dPDK1, y w; EP(3)0837TM2 y males
were treated with EMS according to Lewis and Bacher (20) and
mated to y w; GMR-Gal4 UAS-dAktCyO; MKRSTM2 females.
A total number of 2,300 F1 progeny of the genotype y w;
GMR-Gal4 UAS-dAkt; EP(3)0837MKRS or TM2 was
screened for a suppression of the big eye phenotype shown in Fig.
2d. Primary positives were retested, and stocks were established
by balancing the potential dPDK1 alleles with the TM6B y
balancer.
Genomic DNA was extracted from heterozygous flies, and
coding exons of dPDK1 were amplified by PCR. The PCR
products were sequenced and analyzed with SEQUENCHER soft-
ware for the appearance of double peaks in the sequence
chromatogram, and compared with the published sequence (21).
The nucleotide changes are: dPDK13 (GGT3AGT), dPDK14
(CCG3CTG), dPDK15 (CAG3TAG).
Clonal Analysis. Clonal analysis of dPDK1 loss-of-function alleles
was performed by using the FlpFRT and the ey-Flp systems as
described (22, 23). To generate marked clones that express either
EP(3)0837 controlled dPDK1 andor UAS-dAkt in eye disk cells
during the last cell cycle and subsequent differentiation, 24- to
48-h-old larvae containing a heat-shock-inducible Flp recombi-
nase, a Flp-out transgene (GMRFRT w STOP FRTGal4),
the EP(3)0837 element, andor a UAS-dAkt construct were
subjected to a heat shock for 1 h at 37°C. This procedure induces
recombination between the FRT sites of GMRFRT w STOP
FRTGal4 and removes the w STOP cassette in clones, thus
allowing expression of dPDK1 and dAkt under the control of
GMR-Gal4. Histological sections of the eyes were performed as
described (24).
Plasmids and Germ-Line Transformation. To generate UAS-dPDK1,
the ORF coding for dPDK1 was amplified from the full-length
cDNA clone LD16509 (obtained from Research Genetics,
Huntsville, AL) by PCR by using the primers 5-GGAATTCAT-
GGCCAAGGAGAAAGCATC-3 (ofr77) and 5-GCTCTA-
GACGTTTACTTAGACGCCGTC-3 (ofr80), which intro-
duced EcoRI and XbaI sites at the 5 and 3 ends, respectively.
The PCR product was ligated into the pUAST Drosophila
transformation vector (25), and the resulting plasmid UAS-
dPDK1 was used for transformation.
To generate UAS-PDK1A467V the point mutation C3T at
dPDK1 nucleotide position 2,032 was introduced with a Quick-
Change Site-Directed Mutagenesis Kit from Stratagene. For
PCR we used the primers 5-GTTTATCAGATGATCGTCG-
GCCTACCGCCATTC-3 and 5-GAATGGCGGTAGGC-
CGACGATCATCTGATAAAC-3 and the pBluescript SK()
plasmid containing the cDNA clone LD16509 as a template. The
resulting plasmid was used as a template for PCR with primers
ofr77 and ofr80. The PCR product was digested with EcoRI and
XbaI and cloned into the pUAST vector. The resulting plasmid
UAS-PDK1A467V was used for transformation.
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To generate UAS-dPKN and UAS-dRSK we performed PCR by
using as a template double-stranded cDNA derived from 0- to
24-h-old Drosophila embryos (kindly provided by K. Nairz, Uni-
versita¨t Zu¨rich, Zu¨rich, Switzerland) with the following primer
pairs: 5-CGGCGAATTAACGAGAAACC-3 and 5-GGC-
CCGTTAGTAAATCCTTG-3 for dPKN and 5-AACAAAG-
GAACCGCTAGGAG-3 and 5-AAGTAGTCGGACTATCT-
GCC-3 for dRSK. The PCR products were cloned by using the
pCRII-TOPOTA vector system (Invitrogen). Subsequently, the
dPKN and dRSK cDNAs were cut out with Asp-718 and NotI and
ligated into the pUAST vector. The resulting plasmids UAS-dPKN
and UAS-dRSK were used for transformation.
P element-mediated germ-line transformation was performed
as described (26). The constructs were injected into y w embryos.
Several independent transformant lines were established for all
constructs.
Phenotypic Analysis. Unless indicated otherwise, all phenotypic
analyses were done in females. Measurements of cell number,
cell size, and body weight were performed as described (27).
National Institutes of Health IMAGE 1.61 was used to quantify the
size of ommatidia and rhabdomeres by measuring the corre-
sponding area.
Drosophila Strains. EP(3)0837, EP(3)3091, and EP(3)3644 f lies
were obtained from the Bloomington Drosophila Stock Center
(Bloomington, IN). Genomic sequences flanking the 3 end of
the enhancer–promoter (EP) elements was isolated by plasmid
rescue (28), sequenced, and analyzed with use of the Berkeley
Drosophila Genome Project database (Berkeley, CA). The Gal4
driver GMR-Gal4 was a gift of M. Freeman (MRC Laboratory
of Molecular Biology, Cambridge, U.K.), ap-Gal4 was described
in ref. 29, and arm-Gal4 was obtained from the Bloomington
Drosophila Stock Center. The following alleles were used for
genetic interaction studies: DPTENdj189 [a putative null mutation
caused by the insertion of an F element in a coding exon which
disrupts the dPTEN ORF after amino acid 89 (30)], dPTENc494
[encoding a strong hypomorph of dPTEN caused by an EMS-
induced amino acid exchange (G135E) in the active-site motif of
the catalytic domain required for phosphatase activity (31)],
dS6Kl-1 [a putative null mutation generated by imprecise excision
of a P element insertion in the dS6K gene, which removed part
of the first exon, including a portion of the catalytic domain (32)],
and dAkt1 [encoding a kinase dead version of dAkt carrying a
single amino acid substitution (F327I) in the DFG motif in
kinase domain VII (33)]. ap-Gal4 UAS-dS6K f lies are described
in ref. 32. The construction of UAS-dAkt f lies will be described
elsewhere. For overexpression studies in which the EMS-induced
dPDK1 alleles dPDK14 and dPDK15 were used, we induced the
jump-out of the EP element EP(3)0837 from fly stocks dPDK14
and dPDK15 to avoid overexpression of mutant dPDK1 proteins
in a background where Gal4 is expressed. P element mobilization
was achieved by standard genetic techniques.
Results and Discussion
To analyze the function of dPDK1 in Drosophila, we aimed to
generate both gain- and loss-of-function alleles of the kinase.
Drosophila contains a single gene that encodes a kinase that is
highly homologous to PDK1 in its primary sequence and its
domain structure (2). Initially, we identified two EP transposable
elements in the 5 region of the endogenous Drosophila PDK1
gene dPDK1 (Fig. 1a). These EP elements drive expression of
dPDK1 under the control of the Gal4 system (25, 34), allowing
us to test whether dPDK1 and dAkt cooperate in promoting
Fig. 1. Gain- and loss-of-function mutations in the dPDK1 locus. (a) Genomic structure of the dPDK1 locus. One of several reported transcripts (42) represented
by the expressed sequence tag (EST) cDNA LD16509 is shown. Boxes represent exons. Dark boxes indicate the ORF; hatched and gray boxes represent the kinase
and Pleckstrin-homology domains, respectively. EP insertions EP(3)0837, EP(3)3091, and EP(3)3644 are shown as triangles, and the direction of transcription from
the UAS-controlled promoter is marked by arrows. EP(3)3644 inserted 7,081 and EP(3)0837 3,875 nt upstream of the putative start codon (Met). EP(3)3091 inserted
710 bp upstream of the 5 end of exon 3. The three EMS-induced loss-of-function mutations and the activating mutation A467V are shown above exon 4. (b)
Kinase domain alignment of Drosophila, C. elegans, and human PDK1. Dark and gray boxes indicate amino acid identity and similarity, respectively. Amino acid
changes in the dPDK13–5 and dPDK1A467V mutants are shown above the dPDK1 sequence. Note that the amino acid substitutions in dPDK13 (G352S) and dPDK14
(P441L) are in highly conserved amino acid residues.














growth in Drosophila. Overexpression of either kinase in the eye
imaginal disk during the last cell division cycle and subsequent
differentiation showed little effect on the size or the structure of
the eye (Fig. 2 b and c). Co-overexpression of dAkt and dPDK1,
however, led to a significant increase in eye size (Fig. 2d).
Furthermore, analysis of clones of cells in the eye overexpressing
dPDK1 andor dAkt revealed that the observed effect on cell
size is strictly autonomous (Fig. 2 e–g). These results indicate that
overexpression of dPDK1 does not interfere with the normal
differentiation of eye disk cells and that it promotes local growth
through dAkt activation.
To generate loss-of-function alleles of dPDK1, the dominant
eye size phenotype caused by co-overexpression of dPDK1 and
dAkt was reverted by using EMS mutagenesis, leading to three
partial or complete loss-of-function mutations. dPDK13 causes a
G(352) to S substitution in the conserved DFG motif in the
kinase subdomain VII (Fig. 1 a and b). The D residue in this
motif is essential for kinase activity by orienting the ATP-Mg2
complex for phosphotransfer (35–37). dPDK14 causes a P(441) to
L substitution in a conserved residue in kinase subdomain VIII.
In the dPDK15 allele, a Q codon at position 437 in kinase
subdomain VIII is mutated to a STOP codon. Because this latter
mutation results in the formation of a truncated dPDK1 protein
lacking part of the kinase domain and the Pleckstrin-homology
domain, dPDK15 is likely to be a null mutation. A fourth allele
EP(3)3091 (dPDK11), from the Berkeley Drosophila Genome
Project, has an EP element located in the third intron of dPDK1
(Fig. 1a) and is homozygous lethal. It failed to complement
dPDK15 (data not shown), and the lethality was reversed by EP
element excision.
Combinations of loss-of-function alleles provided mutants of
varying strengths. Larvae homozygous for the dPDK15 null allele
or larvae of the dPDK11/5 heteroallelic combination die during
the second instar stage. A less severe reduction in dPDK1
function (dPDK14/5) permits development of viable dPDK1
mutant flies that are delayed 1 day in development and smaller
than their heterozygous siblings, having an 18% reduction in
body weight (Fig. 3 a and d). By measuring the cell density in the
wing, the reduction in size and weight apparently is primarily
caused by a decrease in cell size, because cell number is only
slightly affected (Fig. 3d). The lethality associated with the
dPDK1 null allele and the size defect of dPDK1 hypomorphs was
rescued by ubiquitous expression of a wild-type dPDK1 trans-
gene with armadillo (arm)-Gal4 as a driver. dPDK14/5 male flies
are almost completely sterile, although they show no obvious
defect in sperm morphology and motility and in mating behavior
(data not shown). That loss of zygotic dPDK1 function results in
larval lethality is in contrast to a recent analysis of two dPDK1
mutations caused by the EP insertion EP(3)3091 (dPDK11) or a
10-kb deletion (dPDK12), which were homozygous embryonic
lethal (19). It is possible that the embryonic lethality observed
by Cho et al. (19) is not caused by loss of dPDK1 function but by
a linked lethal mutation on the same chromosome, because no
rescue was attempted, and the phenotype was only analyzed in
Fig. 2. Simultaneous overexpression of dPDK1 and dAkt with GMR-Gal4 increases eye and cell size. (a–d ) Simultaneous overexpression of dPDK1 and dAkt in
the developing third instar eye imaginal disk results in the formation of larger eyes. Scanning electron micrographs of adult eyes of the following genotypes:
(a) OregonR, wild type; (b) y w; GMR-Gal4; EP(3)0837; (c) y w; GMR-Gal4 UAS-dAkt; TM2; (d) y w; GMR-Gal4 UAS-dAkt; TM2EP(3)0837. Although
the overexpression of dPDK1 or dAkt alone results only in a slight, but in the case of dPDK1, significant increase in eye size (b and c), simultaneous expression
of dPDK1 and dAkt causes a substantial increase in eye size (d). The area of at least 29 ommatidia in 3–6 eyes was measured for each genotype. Because the size
of ommatidia of the genotypes y w; GMR-Gal4 UAS-dAkt; TM2 and y w; GMR-Gal4 UAS-dAkt; TM2EP(3)0837 is variable, only the values of the 30%
largest ommatidia were included in the calculation. We used flies of the following genotype, y w; GMR-Gal4UAS-lacZ, as a control. The means of these values
are (normalized to a value of 100  SD): 100  3 (control); 113  3 (b); 108  6 (c); 131  10 (d). (e–g) dPDK1 and dAkt act synergistically to increase cell size
in a cell-autonomous manner. Tangential sections through adult eyes containing clones in which dPDK1 andor dAkt were overexpressed: (e) y w hs-Flpy w;
GMRFRT w STOP FRTGal4; EP(3)0837; ( f) y w hs-Flpy w; GMRFRT w STOP FRTGal4UAS-dAkt; (g) y w hs-Flpy w; GMRFRT w STOP
FRTGal4UAS-dAkt; EP(3)0837. Clones are marked by the lack of red pigment. No increase in cell size is observed by overexpressing dPDK1 or dAkt alone
(e and f ), but simultaneous overexpression of dPDK1 and dAkt slightly increases cell size (g). For quantification, the area of the R6 rhabdomere for 15
photoreceptors in clones overexpressing dPDK1 andor dAkt (white arrowhead) were compared with the corresponding value for the sister control clone in the
same section (yellow arrowhead): The values were normalized to 100 SD for the sister control clone and compared with the value in the overexpression clone:
100 6 vs. 110 7 (e); 100 7 vs. 113 7 ( f); 100 6 vs. 155 10 (g). At the border of the clones, ommatidia composed of wild-type cells and cells overexpressing
dPDK1 andor dAkt are visible, indicating that the increase in cell size in g is cell-autonomous. (Bar  100 m.)
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homozygotes. Consistent with this observation, larvae homozy-
gous for a dPDK11 mutant chromosome, which has been cleaned
from second hits by recombination, die during the second instar
stage. Although it is very likely that dPDK1 functions during
embryogenesis, like dAkt (33), maternal transcripts may be
sufficient to support embryonic development.
To determine whether the effects of loss of dPDK1 function on
cell growth and organ development are autonomous events, we
analyzed loss of dPDK1 in clones of cells by using the FRT mitotic
recombination system (22). In contrast to organism lethality, clones
of cells homozygous for the dPDK1 null allele dPDK15 survive to
adulthood. These cells show no defect in their ability to differentiate
into photoreceptor cells or accessory cells, but mutant photorecep-
tor cells are 30% smaller than the heterozygous cells outside the
clone (Fig. 3b), a strictly cell autonomous effect. To test whether an
entire body part could develop in the absence of dPDK1 function,
dPDK1 was selectively removed in much of the head primordium
by using the ey-Flp system (23). Heads homozygous mutant for
anyone of the three alleles, dPDK13, dPDK14, and dPDK15, are
reduced in size (Fig. 3c; data not shown), which indicates that entire
organs differentiate and develop in the absence of dPDK1 function,
but that the final size of these organs autonomously depends on the
amount of dPDK1 activity. The reduction in head size was most
severe with dPDK15 followed by dPDK14 and dPDK13, with the
complete removal of dPDK1 function similar to that observed for
loss-of-function mutations in the Drosophila insulin receptor (dInr),
Dp110PI(3)K, and dAkt (ref. 27; H.S. and E.H., unpublished
work).
The pronounced effect of loss of dPDK1 function on head size
suggested that it is a dominant constituent in the dInr pathway.
To test this possibility, we examined the ability of complete and
partial loss-of-function alleles of dPDK1 to reverse phenotypes
caused by either overexpression of dInr or by mutations in
dPTEN, the 3-phosphatidylinositide phosphatase. Overexpres-
sion of a wild-type dInr cDNA under the control of GMR-Gal4
led to a marked increase in eye size and a slightly rough eye
surface (27), an effect dominantly suppressed by removing one
copy of dPDK1 (Fig. 4a). Further reduction of dPDK1 function
by the dPDK11/4 heteroallelic combination reduced the eye to
almost wild-type size (Fig. 4b), suggesting that the amount of
dPDK1 protein is rate-limiting for the dInr overgrowth pheno-
type. Null mutations in dPTEN cause lethality, and removal of
dPTEN function in clones stimulates cell autonomous growth
(30, 31, 38), suggesting that increased levels of PIP3 promote
growth and are the likely cause of lethality. Thus, if dPDK1 is an
essential target of PIP3, mutations in dPDK1 may suppress the
dPTEN phenotype. Surprisingly, some dPTENdPDK1 double
mutant flies survive to adulthood (Fig. 4c), indicating that the
presumed PIP3-induced lethality is primarily caused by the
hyperactivation of dPDK1 or of one of its targets.
The fact that the growth phenotypes of dPDK1 mutations are
similar to those caused by mutations in genes coding for dS6K (32),
and dAkt (refs. 39 and 40; H.S. and E.H., unpublished work), and
that S6K1 is a mammalian PDK1 substrate, raised the possibility
that dPDK1 may independently control growth through dS6K. This
possibility was tested in the wing, which is composed of a dorsal and
a ventral epithelial sheet that are tightly attached to each other
through extracellular matrix. We have shown that selective over-
expression of a wild-type dS6K cDNA in the dorsal wing epithelium
with the apterous (ap)-Gal4 driver leads to a bending down of the
wing blade, probably because of a cell-size increase in the dorsal
surface (32). This phenotype was suppressed by a reduction of
dPDK1 function (Fig. 5 a–c). Although ap-Gal4 induced overex-
pression of wild-type dPDK1 alone had little effect on wing
morphology (data not shown), overexpression of a dPDK1A467V
variant was sufficient to cause a bent-wing phenotype (Fig. 5d). The
corresponding amino acid substitution in the C. elegans PDK1 is
thought to cause a hyperactivation of the kinase (18). The
dPDK1A467V-induced bent wing phenotype depends on normal
levels of dS6K and dAkt, because null mutations in either of the
corresponding genes dominantly suppress the phenotype (Fig. 5 e
and f). Together with the biochemical evidence in cultured cells and
in vivo that dPDK1 controls the activity of dAkt and dS6K (ref. 19;
T. Radimerski, J. Montagne, F. R. J. van der Kaay, C. P. Downes,
E.H., and G.T., unpublished work) these results provide functional
evidence that dPDK1 is a key regulator in the control of growth
and cell size by regulating the activity of two AGC kinases, dAkt and
dS6K.
The effects of dPDK1 on dS6K raised the possibility that
dPDK1 controls the activity of other AGC kinases in vivo, such
as dRSK and dPKN, which have been implicated as mammalian
PDK1 substrates. Because the developing eye depends on en-
dogenous levels of dPDK1, we examined whether lowering the
dose of dPDK1 was sufficient to suppress dominantly the rough
eye phenotype caused by overexpression of dRSK and dPKN
under GMR-Gal4 control (Fig. 5g; data not shown). Reduction
of dPDK1 activity in a viable dPDK1 mutant combination was
sufficient to suppress the rough eye phenotype of dRSK but not
Fig. 3. dPDK1 loss-of-function phenotypes. (a) Body size reduction of hetero-
allelic mutant flies. Males (Right) and females (Left) of the following geno-
types are shown: y w; dPDK15 (Top); y w; dPDK14dPDK15 (Bottom). (b)
Tangential section through an eye containing a dPDK15/5 clone. Within the
clone, all photoreceptor cells are reduced in size compared with wild-type
photoreceptor cells. At the border of the clone, ommatidia composed of
phenotypically wild-type and mutant cells (arrowhead) are visible, indicating
that dPDK1 controls cell size autonomously. The genotype is as follows: y w
ey-Flpy w; dPDK15 FRT80BFRT80B. (c) Selective removal of dPDK1 function
from the eye imaginal disk results in a reduction of head and eye size. y w
ey-Flpy w; dPDK15 FRT80BM(3)67c4 FRT80B (Left); OregonR, wild type
(Right). (d) Quantification of body and organ size in dPDK1 heteroallelic
mutant male flies compared with heterozygous and rescued flies, which
overexpress a wild-type dPDK1 cDNA under the control of the ubiquitous
arm-Gal4 driver. Values of y w; dPDK15 (), y w; dPDK14dPDK15 (),
and y w; arm-Gal4UAS-dPDK1; dPDK14dPDK15 flies (resc.) are shown. Values
are the mean  SD.














of dPKN overexpression (Fig. 5g; data not shown). These results
suggest that at least in this in vivo assay, dRSK activity critically
depends on dPDK1 function, whereas dPKN activity is not
changed by a reduction in dPDK1 levels. This idea is in line with
the recent finding that in PDK1/ embryonic stem cells the
protein kinase C-related protein kinase PRK2, which shares
extensive homology with PKN, is still partially phosphorylated at
its T loop residue (41), indicating that PDK1-independent
mechanisms for the phosphorylation of the T loop of certain
AGC kinases including dPKN may exist.
Our results show that dPDK1 is an essential component in the
insulin signaling pathway in the control of cell growth and body size
through its two substrates, dAkt and dS6K. These results are distinct
from the genetic evidence in C. elegans where Akt is the primary
target of PDK1 in dauer formation. Because mutations in the
insulin signaling pathway do not show an autonomous alteration of
cell size in C. elegans, the regulation of the rate of protein synthesis
through S6K does not seem to be a primary target of this pathway.
However, that dPDK1 may yet have additional substrates is sug-
gested by the genetic interaction with dRSK gain-of-function mu-
tations and because viable dPDK1 males are almost completely
sterile. Although mutations in components of the insulin signaling
pathway such as dInr, chico, Dp110PI(3)K, and dAkt cause female
sterility, male sterility is not observed. Further genetic dissection of
dPDK1 function is required to determine the role of dPDK1 in male
fertility. Our findings in Drosophila are consistent with the absence
of insulin growth factor-1-induced activation of S6K, Akt, and RSK
in mammalian PDK1/ embryonic stem cells (17), and therefore
provide evidence for the functional conservation of branch points
in kinase networks during evolution.
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Fig. 4. dPDK1 loss-of-function mutations suppress dInr and dPTEN mutant phenotypes. (a and b) The eye phenotype caused by overexpression of UAS-dInr with
the GMR-Gal4 driver is dominantly suppressed by removing one copy of dPDK1, and the eye size is almost completely restored to wild-type size in a dPDK11/4
heteroallelic mutant background, although eye roughness is increased. The reason for this latter observation is unclear. (a) y w; GMR-Gal4 UAS-dInr; dPDK15
(Left); y w; GMR-Gal4 UAS-dInr; MKRS (Right); (b) y w; GMR-Gal4 UAS-dInr; dPDK11dPDK14 (Left); y w; GMR-Gal4 UAS-dInr; dPDK14 (Right). (c)
The lethality caused by mutations in dPTEN is rescued in a dPDK1 heteroallelic mutant background: Some dPTEN, dPDK1 double-mutant flies survive to
adulthood, although they display mutant phenotypes like an unproportionally reduced size of the abdomen and deformed leg structures. Similar phenotypes
have been observed in partial loss-of-function mutations for dTOR (S. Oldham and E.H., unpublished work). Flies of the following genotypes are shown: y w
dPTENdj189dPTEN494; dPDK14dPDK15 (Upper), OregonR, wild-type (Lower).
Fig. 5. Genetic interaction of dPDK1 with the AGC kinases dAkt, dS6K, and
dRSK. (a–c) Mutations in dPDK1 suppress the ap-Gal4 UAS-dS6K bent-wing
phenotype. (a) y w; ap-Gal4 UAS-dS6K; MKRS; (b) y w; ap-Gal4 UAS-
dS6K; dPDK15; (c) y w; ap-Gal4 UAS-dS6K; dPDK14dPDK15. (d–f ) Null
mutations in dS6K and dAkt dominantly suppress the ap-Gal4 UAS-
dPDK1A467V bent-wing phenotype. (d) y w; ap-Gal4 UAS-dPDK1A467V; (e) y
w; ap-Gal4 UAS-dPDK1A467V; dS6Kl-1; ( f) y w; ap-Gal4 UAS-
dPDK1A467V; dAkt1. (g) Mutations in dPDK1 suppress the rough eye
phenotype caused by overexpression of UAS-dRSK under GMR-Gal4 control. y
w; GMR-Gal4 UAS-dRSK; dPDK15 (Left); y w; GMR-Gal4 UAS-dRSK;
dPDK14dPDK15 (Right).
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